The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled
study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's
Disease taking a stable dose of donepezil (Aricept.) Its objective is to assess the efficacy
of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive
function, global function and plasma and neuroimaging biomarkers.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
National Institute on Aging (NIA) Tolmar Pharmaceuticals